Market Synopsis of Global Xanthoma Market
Xanthoma is a dermatologic condition in which fat grows underneath the skin, which vary in size ranging from a pinhead to as large as a grape. They usually appear like a flat bump under the skin and sometimes yellow or orange colored. They usually don’t cause any pain with some minor irritation such as tenderness and itchy feeling. There may be clusters of growths in the same area or several individual growths on different parts of the body. The exact causes of xanthoma are unknown, however, genetic factors have been indicated such as cognosis type 1a, autosomal recessive hypercholesterolemia, alagille syndrome and cholestanol storage disease.
The risk factors for xanthoma are high levels of blood lipids, or fats, hyperlipidemia, or high blood cholesterol levels, diabetes, cancer, hypothyroidism, biliary cirrhosis, cholestasis, nephrotic syndrome, hematologic diseases such as monoclonal gammopathy and other metabolic disorders. A side effect of certain medications, such as tamoxifen, prednisone, cyclosporine, and others.
View Reports Sample @ https://www.marketresearchfuture.com/sample_request/4860
The market drivers of the global xanthoma market are rising demand due to growing population, increasing screening, greater emphasis on restorative procedures, rising safety and success of xanthoma treatment, and others. However, the complications such as the risk of bleeding, infections, pain, especially, during surgery, the high cost of xanthoma treatment, poor understanding for the disease and others may hamper the market growth over the forecast period.
The global xanthoma market is expected to reach USD 8.0 billion by 2023, and the market is projected to grow at a CAGR of ~ 6.0 % during the forecast period 2017-2023.
- Global Xanthoma manufacturers & suppliers
- Research and development (R&D) companies
- Hospitals and clinics
- Academic institutes and universities
The global xanthoma market has been segmented on the basis of types, diagnosis, treatment, and end user.
Based on the types, the market has been segmented into xanthelasma, xanthoma tuberosum, xanthoma tendinosum, eruptive xanthoma, xanthoma planum, palmar xanthoma, tuberoeruptive xanthoma and others.
Based on the diagnosis, the market has been segmented as physical examination, biopsy, blood tests, and others.
Based on the treatment, the market has been segmented as drugs, surgery, chemical treatment and others.
Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.
The Americas account for a significant market share owing to high expenditure on the health care, especially, of the U.S. and Canada. Additionally, the greater number of dermatology procedures due to greater healthcare penetration in the U.S. and Canada drives the xanthoma market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of dermatology procedures, especially, the xanthoma surgery treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause of faster development of the xanthoma market in the US.
Europe is the second largest market in the world due to the growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to the large pharmaceutical industry.
Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast-growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future xanthoma market in the region.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt, and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to the poor social development and tribal identities such as sub-Saharan Africa.
Request Full Report @ https://www.marketresearchfuture.com/reports/xanthoma-market-4860
Key Players in the Global Xanthoma Market
Some of the key players profiled in the report are AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Bayer HealthCare Pharmaceuticals LLC, Pfizer, Inc., Novartis International AG, Teva pharmaceutical industries, Novo Nordisk, and Sanofi.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar